Current landscape of direct-to-consumer genetic testing and its role in ophthalmology: A review

11Citations
Citations of this article
57Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The sequencing of the human genome has seen the emergence of the direct-to-consumer (DTC) genetic-testing market, which allows individuals to obtain information about their genetic profile and its many health and lifestyle implications. Genetics play an important role in the development of many eye diseases, however, little information is available describing the influence of the DTC industry in ophthalmology. In this review, we examined DTC companies providing genetic test products for eye disease. Of all eye conditions, the majority of DTC companies provided susceptibility testing or risk assessment for age-related macular degeneration (AMD). For the 15 companies noted to offer products, we found considerable variation in the cost, scope and clarity of informational content of DTC genetic testing for ophthalmic conditions. The clinical utility of these tests remains in question, and the American Academy of Ophthalmology recommendations against routine testing for many conditions probably still apply.

Cite

CITATION STYLE

APA

Sanfilippo, P. G., Kearns, L. S., Wright, P., Mackey, D. A., & Hewitt, A. W. (2015, August 1). Current landscape of direct-to-consumer genetic testing and its role in ophthalmology: A review. Clinical and Experimental Ophthalmology. https://doi.org/10.1111/ceo.12508

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free